Abstract
Methylprednisolone (MP) is usually used to reduce inflammation reaction and tissue damage, which may have a beneficial treatment effect on coronavirus disease 2019 (COVID-19). However, we present the case of a child who manifests significant bradycardia with the use of just low dose MP on the premise of the long-term use of arbidol. Arbidol can affect the activity of CYP3A4, which is also a key metabolic enzyme of MP by competitive inhibition, and which is easy to aggravate the side effects of MP. Therefore, more attention should be paid to bradycardia occurrence in the patient with COVID-19 when MP is considered in COVID-19.
Keywords: coronavirus; infection; inflammation.
All Keywords
【저자키워드】 coronavirus, Infection, Inflammation., 【초록키워드】 COVID-19, Methylprednisolone, Treatment, coronavirus disease, Inflammation, Coronavirus disease 2019, Arbidol, Child, low dose, CYP3A4, Side effects, bradycardia, Side effect, tissue damage, enzyme, premise, Affect, competitive inhibition, Occurrence, the patient, reduce, aggravate, with COVID-19, 【제목키워드】 low dose, with COVID-19,
【저자키워드】 coronavirus, Infection, Inflammation., 【초록키워드】 COVID-19, Methylprednisolone, Treatment, coronavirus disease, Inflammation, Coronavirus disease 2019, Arbidol, Child, low dose, CYP3A4, Side effects, bradycardia, Side effect, tissue damage, enzyme, premise, Affect, competitive inhibition, Occurrence, the patient, reduce, aggravate, with COVID-19, 【제목키워드】 low dose, with COVID-19,
{{{ 추상적인 }}}
메틸프레드니솔론(MP)은 일반적으로 염증 반응과 조직 손상을 줄이는 데 사용되며, 이는 2019년 코로나바이러스(COVID-19)에 유익한 치료 효과가 있을 수 있습니다. 그러나 우리는 arbidol의 장기간 사용을 전제로 낮은 용량의 MP를 사용하여 심각한 서맥을 나타내는 어린이의 경우를 제시합니다. Arbidol은 경쟁 억제에 의해 MP의 주요 대사 효소이기도 한 CYP3A4의 활성에 영향을 줄 수 있으며 MP의 부작용을 악화시키기 쉽습니다. 따라서 COVID-19에서 MP를 고려할 때 COVID-19 환자에서 서맥 발생에 더 많은주의를 기울여야합니다.
{{ 키워드: }} 코로나바이러스; 전염병; 염증.